World's largest Science, Technology & Medicine Open Access book publisher
Chapter 7 from the book People's Movements in the 21st Century - Risks, Challenges and Benefits
Int. J. Mol. Sci. 2017, 18, 341, 1 - 10
Clinical Medicine
JCI Insight. 2017;2(7):e91963.
Trials (2017) 18:152, DOI 10.1186/s13063-017-1881-z
Practical Guidance for collaborative interventions
The Community Action Research on Disability (CARD) programme in Uganda embraced and modified the EDR approach, recognising the need for including people with disability in the research process from concept to outcome, and nurturing participation and collaboration between all the stakeholders in achi...eving action-based research. T
more
PLOS ONE | DOI:10.1371/journal.pone.0172392 February 16, 2017
WHO working group on HIV incidence assays meeting report
10–11 December 2015
Glion, Switzerland
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
WHO/HIV/2017.03
Topics in Antiviral Medicine Volume 25 Issue 2 May/June 2017
Review
www.co-hivandaids.com
Volume 12 Number 4 July 2017
Lessons from the STEP-TB Project.
Accessed November 2017.
A review of available evidence (2016).
28-29 June 2016; Geneva, Switzerland
The END TB strategy.
Application of a One Health approach .
The present guidance was developed with the support of the WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR) to assist countries and other stakeholders in the establishment and development of programmes of integrated surveillan...ce of antimicrobial resistance in the foodborne bacteria (i.e., bacteria commonly transmitted by food) by taking a One Health approach.
more
Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more